Sugi Predict

Sugi Predict / Compounds / SCHEMBL30311133

SCHEMBL30311133

SCHEMBL30311133

CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CS)C(N)=O

nearest known ligand 0.58

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ KISS1R Q969F8 5/20 0.58
▸ CCKBR P32239 3/20 0.58
▸ CXCR4 P61073 3/20 0.57
▸ CXCL8 P10145 7/20 0.57
▸ GLP1R P43220 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30310985 0.92 CXCL8 (0.61) KISS1RCCKBRCXCL8
SCHEMBL7401387 0.86 KISS1R (0.63) KISS1RCXCL8
SCHEMBL30511828 0.85 NPY1R (0.61) KISS1RCCKBRCXCL8GLP1R
SCHEMBL31606506 0.85 KISS1R (0.61) KISS1RCCKBRCXCL8GLP1R
SCHEMBL29716758 0.84 CXCR4 (0.60) CCKBRCXCR4GLP1R
SCHEMBL31083903 0.84 F13A1 (0.52) KISS1RCCKBRCXCR4GLP1R
SCHEMBL30310961 0.84 CXCL8 (0.61) KISS1RCCKBRCXCL8
SCHEMBL31083911 0.84 CXCL8 (0.64) KISS1RCCKBRCXCR4CXCL8
SCHEMBL31199030 0.84 CXCL8 (0.57) KISS1RCCKBRCXCR4CXCL8
SCHEMBL29440225 0.84 TACR1 (0.59) KISS1RCXCR4CXCL8GLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250296971-A1 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2025-09-25 — — US disclosed
EP-4423110-A2 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B Pharmaceuticals GmbH (DE) 2024-09-04 — — EP disclosed
WO-2023072971-A2 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2023-05-04 — — WO disclosed
EP-4170347-A1 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B Pharmaceuticals GmbH (DE) 2023-04-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250296971-A1 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS GIPR, VIP, GRPR KISS1R 91/4885CCKBR 4/4885CXCR4 421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback